172 related articles for article (PubMed ID: 22443173)
1. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial.
Higurashi T; Takahashi H; Endo H; Hosono K; Yamada E; Ohkubo H; Sakai E; Uchiyama T; Hata Y; Fujisawa N; Uchiyama S; Ezuka A; Nagase H; Kessoku T; Matsuhashi N; Yamanaka S; Inayama Y; Morita S; Nakajima A
BMC Cancer; 2012 Mar; 12():118. PubMed ID: 22443173
[TBL] [Abstract][Full Text] [Related]
2. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
[TBL] [Abstract][Full Text] [Related]
4. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
[TBL] [Abstract][Full Text] [Related]
6. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A
Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Takayama T; Nagashima H; Maeda M; Nojiri S; Hirayama M; Nakano Y; Takahashi Y; Sato Y; Sekikawa H; Mori M; Sonoda T; Kimura T; Kato J; Niitsu Y
Clin Cancer Res; 2011 Jun; 17(11):3803-11. PubMed ID: 21385928
[TBL] [Abstract][Full Text] [Related]
8. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
10. A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index.
Zell JA; McLaren CE; Morgan TR; Lawson MJ; Rezk S; Albers CG; Chen WP; Carmichael JC; Chung J; Richmond E; Rodriguez LM; Szabo E; Ford LG; Pollak MN; Meyskens FL
Cancer Prev Res (Phila); 2020 Feb; 13(2):203-212. PubMed ID: 31818851
[TBL] [Abstract][Full Text] [Related]
11. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.
Wali RK; Bianchi L; Kupfer S; De La Cruz M; Jovanovic B; Weber C; Goldberg MJ; Rodriguez LM; Bergan R; Rubin D; Tull MB; Richmond E; Parker B; Khan S; Roy HK
PLoS One; 2018; 13(4):e0193544. PubMed ID: 29617381
[TBL] [Abstract][Full Text] [Related]
12. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
Petrera M; Paleari L; Clavarezza M; Puntoni M; Caviglia S; Briata IM; Oppezzi M; Mislej EM; Stabuc B; Gnant M; Bachleitner-Hofmann T; Roth W; Scherer D; Haefeli WE; Ulrich CM; DeCensi A
BMC Cancer; 2018 Dec; 18(1):1210. PubMed ID: 30514262
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
14. Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Thent ZC; Zaidun NH; Azmi MF; Senin MI; Haslan H; Salehuddin R
Curr Drug Targets; 2017; 18(6):734-750. PubMed ID: 27919208
[TBL] [Abstract][Full Text] [Related]
15. Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Crawley D; Chandra A; Loda M; Gillett C; Cathcart P; Challacombe B; Cook G; Cahill D; Santa Olalla A; Cahill F; George G; Rudman S; Van Hemelrijck M
BMC Cancer; 2017 Jul; 17(1):494. PubMed ID: 28732480
[TBL] [Abstract][Full Text] [Related]
16. ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
Drew DA; Chin SM; Gilpin KK; Parziale M; Pond E; Schuck MM; Stewart K; Flagg M; Rawlings CA; Backman V; Carolan PJ; Chung DC; Colizzo FP; Freedman M; Gala M; Garber JJ; Huttenhower C; Kedrin D; Khalili H; Kwon DS; Markowitz SD; Milne GL; Nishioka NS; Richter JM; Roy HK; Staller K; Wang M; Chan AT
Trials; 2017 Feb; 18(1):50. PubMed ID: 28143522
[TBL] [Abstract][Full Text] [Related]
17. Metformin suppresses intestinal polyp growth in ApcMin/+ mice.
Tomimoto A; Endo H; Sugiyama M; Fujisawa T; Hosono K; Takahashi H; Nakajima N; Nagashima Y; Wada K; Nakagama H; Nakajima A
Cancer Sci; 2008 Nov; 99(11):2136-41. PubMed ID: 18803638
[TBL] [Abstract][Full Text] [Related]
18. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants.
Hofstad B; Almendingen K; Vatn M; Andersen SN; Owen RW; Larsen S; Osnes M
Digestion; 1998; 59(2):148-56. PubMed ID: 9586828
[TBL] [Abstract][Full Text] [Related]
19. Colon epithelial proliferation and carcinogenesis in diet-induced obesity.
Takahashi H; Hosono K; Endo H; Nakajima A
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():41-7. PubMed ID: 24251703
[TBL] [Abstract][Full Text] [Related]
20. Metformin as an antitumor agent in cancer prevention and treatment.
Li D
J Diabetes; 2011 Dec; 3(4):320-7. PubMed ID: 21631893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
